Acadia to Move Experimental Pediatric Rett Syndrome Drug to Phase 3

Acadia Pharmaceuticals said it plans to advance a drug it licensed last year from Australia’s Neuren Pharmaceuticals into a late-stage trial following promising Phase 2 results of the potential Rett syndrome treatment.